Immunotherapy

• Basic Principles of Immunotherapy and Melanoma
• JVDF Trial Results Reported For Ramucirumab Plus Pembrolizumab
• Can We Increase the Immunogenicity in MSS CRC?
• How to Improve the Results With IO Agents in MSI GI Cancer
• The Link Between the Immune Microenvironment and Outcome in Colorectal Cancer
• Understanding Relevant Immune Pathways By the Oncologist
• How to Integrate New Agents in HCC (Sequence of Treatment): The Role of Checkpoint Inhibitors
• Keynote Lecture: Managing Side Effects of IO Agents
• Check-Point Inhibitors in Esophageal and Gastric Cancer: When and for Whom?
• ESMO Advanced Course on Lung Cancer in Immunotherapy July 2019
• Toxicity issues with Immune Check Points inhibitors
• The point of view of the Immunologist
• What is the rational for adding anti-angiogenics to Immune Check-Point Inhibitors?
• In TPS>50%, what is best in 1st-line: single agent Pembrolizumab or CT-IO combination?
• Debate Pro: one size fits all!
• State-of-the-art: Immunotherapy with Immune Check Point Inhibitors of Locally Advanced and Metastatic Non-Small Cell Lung Cancer in 1st and later l...
• Corticosteroid Link To NSCLC Immunotherapy Response Challenged
• Niraparib Plus Pembrolizumab ‘Promising’ For Advanced TNBC, Ovarian Cancer
• Expert video report on breast cancer
• ASCO 2019: Highlights on results from the KEYNOTE 062 study
• Expert video report on breast cancer
• Immunotherapy in Gastrointestinal Cancers
• Participant Clinical Case Discussion: Complete Remission of Metastatic Rectal Cancer After Panitumumab Containing Chemotherapy
• EGFR Mutation Allele Influences NSCLC Immune Checkpoint Inhibitor Response
• Expert video report on Targeting NTRK gene fusions across cancers

• « Previous
• 1
• 2
• ...
• 87
• Next »